Combination of adjuvants: The future of vaccine design

Expert Review of Vaccines

Volumn 12, Issue 7, 2013, Pages 733-746

  Mount, Adele ^a   Koernig, Sandra ^a   Silva, Anabel ^a   Drane, Debbie ^b   Maraskovsky, Eugene ^a   Morelli, Adriana Baz ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

adjuvants; ISCOMATRIX adjuvant; Toll like receptor; vaccines

Indexed keywords

AGATOLIMOD; ALPHA TOCOPHEROL; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; ANTHRAX VACCINE; AS 01; AS 02; AS 04; AS 15; BCG VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; IMMUVAC; INFLUENZA VACCINE; ISA 51; ISCOMATRIX; ISCOPREP; MIFAMURTIDE; MONTANIDE; MONTANIDE ISA 51; PATTERN RECOGNITION RECEPTOR; QS 21; RESIQUIMOD; SIPULEUCEL T; SQUALENE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG DESIGN; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; VACCINATION; VACCINES;

EID: 84880900133     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.811185     Document Type: Review

References (114)

1. Leroux-Roels G. Unmet needs in modern vaccinology: Adjuvants to improve the immune response. Vaccine 28(Suppl. 3), C25-C36 (2010
2. Aurisicchio L, Ciliberto G. Patented cancer vaccines: The promising leads. Expert Opin. Ther. Pat. 20(5), 647-660 (2010
3. Qu L, Lemon SM. Hepatitis A and hepatitis C viruses: Divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Semin. Liver Dis. 30(4), 319-332 (2010
4. Marsili G, Remoli AL, Sgarbanti M, Perrotti E, Fragale A, Battistini A. HIV-1, interferon and the interferon regulatory factor system: An interplay between induction, antiviral responses and viral evasion. Cytokine Growth Factor Rev. 23(4-5), 255-270 (2012
5. Singh Y, Kaul V, Mehra A et al. Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity. J. Biol. Chem. 288(7), 5056-5061 (2013
6. Blomgran R, Desvignes L, Briken V, Ernst JD. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe 11(1), 81-90 (2012
7. Woodworth JS, Shin D, Volman M, Nunes-Alves C, Fortune SM, Behar SM. Mycobacterium tuberculosis directs immunofocusing of CD8+ T cell responses despite vaccination. J. Immunol. 186(3), 1627-1637 (2011
8. Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin. Biol. Ther. 7(8), 1275-1280 (2007
9. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287-293 (2009
10. Podda A. The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-Adjuvanted vaccine. Vaccine 19(17-19), 2673-2680 (2001
11. Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: A review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 22(5), 279-292 (2008
12. Geeraedts F, Huckriede A. Influenza vaccines: What do we want and how can we get it? Adv. Exp. Med. Biol. 780, 161-174 (2011
13. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: A phoenix that arose from the ashes. Expert Rev. Vaccines 12(1), 13-30 (2013
14. Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing a-Tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11(3), 349-366 (2012
15. Bovier PA. Epaxal: A virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines 7(8), 1141-1150 (2008
16. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines 6(2), 133-140 (2007
17. Szarewski A. Cervarix®: A bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev. Vaccines 11(6), 645-657 (2012
18. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4), 492-503 (2010
19. Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543-547 (2011
20. Kawai T, Akira S. The role of patternrecognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11(5), 373-384 (2010
21. Harandi AM, Medaglini D, Shattock RJ; Working Group convened by EUROPRISE. Vaccine adjuvants: A priority for vaccine research. Vaccine 28(12), 2363-2366 (2010
22. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227(1), 221-233 (2009
23. Kabelitz D, Medzhitov R. Innate immunity-cross-Talk with adaptive immunity through pattern recognition receptors and cytokines. Curr. Opin. Immunol. 19(1), 1-3 (2007
24. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 29(17), 3341-3355 (2011
25. Querec T, Bennouna S, Alkan S et al Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203(2), 413-424 (2006
26. Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S et al. Combination adjuvants: The next generation of adjuvants? Expert Rev. Vaccines 10(1), 95-107 (2011
27. Heldwein KA, Liang MD, Andresen TK et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J. Leukoc. Biol. 74(2), 277-286 (2003
28. Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 104(1), 22-27 (2013
29. Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol. 10(4), 243-254 (2012
30. Zaheer SA, Mukherjee R, Ramkumar B et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J. Infect. Dis. 167(2), 401-410 (1993
31. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26(8), 447-454 (2005
32. Geddes K, Magalhad;es JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat. Rev. Drug Discov. 8(6), 465-479 (2009
33. Agnandji ST, Lell B, Fernandes JF et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med 367(24), 2284-2295 (2012
34. Goldinger SM, Dummer R, Baumgaertner P et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8? T-cell responses in melanoma patients. Eur. J. Immunol. 42(11), 3049-3061 (2012
35. Remarque EJ, Roestenberg M, Younis S et al. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS ONE 7(6), e38898 (2012
36. Leroux-Roels I, Forgus S, De Boever F et al.; M72 Study Group. Improved CD4? T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial. Vaccine 31(17), 2196-2206 (2013
37. Van Braeckel E, Bourguignon P, Koutsoukos M et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin. Infect. Dis. 52(4), 522-531 (2011
38. Sokal EM, Hoppenbrouwers K, Vandermeulen C et al. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196(12), 1749-1753 (2007
39. Fourcade J, Kudela P, Andrade Filho PA et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J. Immunother. 31(8), 781-791 (2008
40. Karbach J, Gnjatic S, Bender A et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: Association with survival. Int. J. Cancer 126(4), 909-918 (2010
41. Sabbatini P, Tsuji T, Ferran L et al. Phase I trial of overlapping long peptides from a tumor self-Antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18(23), 6497-6508 (2012
42. Galluzzi L, Vacchelli E, Eggermont A et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 1(5), 699-716 (2012
43. Luo Y, Knudson MJ. Mycobacterium bovis bacillus Calmette-Gué;rin- induced macrophage cytotoxicity against bladder cancer cells. Clin. Dev. Immunol. 2010, 357591 (2010
44. Stewart JH 4th, Levine EA. Role of bacillus Calmette-Gué;rin in the treatment of advanced melanoma. Expert Rev. Anticancer Ther. 11(11), 1671-1676 (2011
45. Wille-Reece U, Flynn BJ, Loré; K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203(5), 1249-1258 (2006
46. Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: A review of clinical trials. Expert Rev. Vaccines 4(3), 329-350 (2005
47. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: Emerging therapeutics? Nat. Rev. Drug Discov. 9(4), 293-307 (2010
48. Vacchelli E, Galluzzi L, Eggermont A et al. Trial watch: FDA-Approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1(6), 894-907 (2012
49. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6), 973-983 (1996
50. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394-397 (1997
51. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: An update. Cytokine 43(3), 342-349 (2008
52. Zhu Q, Egelston C, Vivekanandhan A et al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines. Proc. Natl Acad. Sci. USA 105(42), 16260-16265 (2008
53. O'Neill LA. When signaling pathways collide: Positive and negative regulation of toll-like receptor signal transduction. Immunity 29(1), 12-20 (2008
54. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769-776 (2005
55. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52(8), 2313-2322 (2005
56. Ghosh TK, Mickelson DJ, Fink J et al. Toll-like receptor (TLR) 2-9 agonistsinduced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell. Immunol. 243(1), 48-57 (2006
57. Hong X, Tong S. Cortical functional connectivity under different auditory attentional efforts. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2012, 6196-6199 (2012
58. Lim SN, Kuhn S, Hyde E, Ronchese F. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy. J. Immunother. 35(9), 670-679 (2012
59. Grossmann C, Tenbusch M, Nchinda G et al. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-Targeted antigens by synergistic toll-like receptor ligands. BMC Immunol. 10, 43 (2009
60. Zhu Q, Egelston C, Gagnon S et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120(2), 607-616 (2010
61. Whitmore MM, DeVeer MJ, Edling A et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64(16), 5850-5860 (2004
62. Wiley SR, Raman VS, Desbien A et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3(93), 93ra69 (2011
63. Garin A, Meyer-Hermann M, Contie M et al. Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. Immunity 33(1), 84-95 (2010
64. Ichinohe T, Ainai A, Ami Y et al. Intranasal administration of adjuvantcombined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J. Med. Virol. 82(10), 1754-1761 (2010
65. Ainai A, Ichinohe T, Tamura S et al. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J. Med. Virol. 82(3), 476-484 (2010
66. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239(1), 178-196 (2011
67. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008
68. Harris J, Sharp FA, Lavelle EC. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur. J. Immunol. 40(3), 634-638 (2010
69. Fritz JH, Le Bourhis L, Sellge G et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26(4), 445-459 (2007
70. Traub S, von Aulock S, Hartung T, Hermann C. MDP and other muropeptides -direct and synergistic effects on the immune system. J. Endotoxin Res. 12(2), 69-85 (2006
71. Schwarz H, Posselt G, Wurm P, Ulbing M, Duschl A, Horejs-Hoeck J TLR8 and NOD signaling synergistically induce the production of IL-1β and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2. Immunobiology 218(4), 533-542 (2013
72. Tada H, Aiba S, Shibata K, Ohteki T, Takada H. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect. Immun. 73(12), 7967-7976 (2005
73. Uehara A, Yang S, Fujimoto Y et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2-And NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell. Microbiol. 7(1), 53-61 (2005
74. Schiller JT, Castellsagué; X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl. 10), K53-K61 (2008
75. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/ aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33-34), 5937-5949 (2006
76. Paavonen J, Jenkins D, Bosch FX et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(9580), 2161-2170 (2007
77. Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 369(9574), 1693-1702 (2007
78. Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95(11), 1459-1466 (2006
79. Han JE, Wui SR, Park SA et al. Comparison of the immune responses to the CIA06-Adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. Vaccine 30(28), 4127-4134 (2012
80. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-Analysis of longitudinal studies. AIDS 20(1), 73-83 (2006
81. Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 30(46), 6541-6550 (2012
82. Gershon AA, Arvin AM, Levin MJ, Seward JF, Schmid DS. Varicella vaccine in the United States: A decade of prevention and the way forward. J. Infect. Dis. 197(Suppl. 2), S39-S40 (2008
83. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 30(20), 3126-3135 (2012
84. Wui SR, Kim HK, Han JE et al. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice. Int. Immunopharmacol. 11(9), 1195-1204 (2011
85. Grabenstein JD. Anthrax vaccine: A review. Immunol. Allergy Clin. North Am. 23(4), 713-730 (2003
86. Bossi P, Tegnell A, Baka A et al.; Task Force on Biological and Chemical Agent Threats, Public Health Directorate, European Commission, Luxembourg. Bichat guidelines for the clinical manage-ment of anthrax and bioterrorism-related anthrax. Euro Surveill. 9(12), E3-E4 (2004
87. Gu M, Hine PM, James Jackson W, Giri L, Nabors GS Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 25(3), 526-534 (2007
88. Tross D, Klinman DM. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J. Immunol. 181(8), 5785-5790 (2008
89. Rynkiewicz D, Rathkopf M, Sim I et al. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 29(37), 6313-6320 (2011
90. Yang M, Yan Y, Fang M et al. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. Int. Immunopharmacol. 13(4), 408-416 (2012
91. Gong M, Zhou J, Yang C et al. Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate. Vaccine 30(52), 7498-7505 (2012
92. Ghandi MK, Khanna R. Human cytomegalovirus: Clinical aspects, immune regulation and emerging treatments. Lancet Infect. Dis. 4(12), 725-738 (2004
93. Crough T, Khanna R. Immunobiology of human cytomegalovirus: From bench to bedside. Clin. Microb. Rev. 22(1), 76-98 (2009
94. Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immunestimulating complex induces specific immunity against multiple strains of cytomegalovirus. J. Gen. Virol. 92(Pt 5), 1021-1031 (2011
95. Naarding MA, Falkowska E, Xiao H, Dragic T. Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice. Vaccine 29(16), 2910-2917 (2011
96. Zhan N, Xiu BS, Wang GH et al. Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen. Virol. J. 8, 507 (2011
97. Lee CJ, Lee LH, Frasch CE. Protective immunity of pneumococcal glycoconjugates. Crit. Rev. Microbiol. 29(4), 333-349 (2003
98. Denoël P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 29(33), 5495-5501 (2011
99. Philipp MT, Purcell JE, Martin DS et al. Experimental infection of rhesus macaques with Streptococcus pneumoniae: A possible model for vaccine assessment. J. Med. Primatol. 35(3), 113-122 (2006
100. Safari D, Dekker HA, Rijkers G, Snippe H. Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates. Vaccine 29(4), 849-854 (2011
101. Drane D, Boyle J, Maraskovsky E. ISCOMATRIXTM adjuvant for prophylactic and therapeutic vaccines. Expert Review of Vaccines 6(5), 761-772 (2005
102. Duewell P, Kisser U, Heckelsmiller K et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J. Immunol. 187(1), 55-63 (2011
103. Wilson NS, Yang B, Morelli AB et al. ISCOMATRIX vaccines mediate CD8+T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol. Cell Biol. 90(5), 540-552 (2012
104. Mckenzie A, Gittleson C. ISCOMATRIX® vaccines: Safety in human clinical studies. Human Vaccines 6(3), 237-246 (2010
105. Jacobs C, Duewell P, Heckelsmiller K et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int. J. Cancer 128(4), 897-907 (2011
106. Middleton D, Rockman S, Pearse M et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J. Virol. 83(15), 7770-7778 (2009
107. Simmons DP, Canaday DH, Liu Y et al. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J. Immunol. 185(4), 2405-2415 (2010
108. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5(8), 800-808 (2004
109. Rehli M. Of mice and men: Species variations of Toll-like receptor expression. Trends Immunol. 23(8), 375-378 (2002
110. Belderbos ME, van Bleek GM, Levy O et al. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: Low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin. Immunol. 133(2), 228-237 (2009
111. Nguyen M, Leuridan E, Zhang T et al. Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS ONE 5(4), e10407 (2010
112. van Duin D, Mohanty S, Thomas V et al. Age-Associated defect in human TLR-1/2 function. J. Immunol. 178(2), 970-975 (2007
113. Shaw AC, Panda A, Joshi SR, Qian F, Allore HG, Montgomery RR. Dysregulation of human Toll-like receptor function in aging. Ageing Res. Rev. 10(3), 346-353 (2011
114. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012